Since the baseline of MRC CFAS there has been an increase in life expectancy, changes in major chronic disease and potentially advances in symptomatic treatments for Alzheimer’s disease and other dementias. CFAS II builds upon the design and infrastructure of MRC to investigate the implications of changes in morbidity and frailty on health itself, as well as the use of services and expenditure in health and social care on future. It also provides important baseline information on older people aged 65-84 in 2008-2011 who will reach the age of greatest frailty during the 2020’s, when the peak in the number of people aged 85 or over is expected and at a time when major therapeutic interventions for dementia could be expected to have an effect.